| Literature DB >> 26147744 |
Yoav Ben-Shlomo1, Simon M Collin2, James Quekett3, Jonathan A C Sterne1, Penny Whiting4.
Abstract
BACKGROUND: There is little evidence on how best to present diagnostic information to doctors and whether this makes any difference to clinical management. We undertook a randomised controlled trial to see if different data presentations altered clinicians' decision to further investigate or treat a patient with a fictitious disorder ("Green syndrome") and their ability to determine post-test probability.Entities:
Mesh:
Year: 2015 PMID: 26147744 PMCID: PMC4492926 DOI: 10.1371/journal.pone.0128637
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Hypothetical scenario and background information about “Green Syndrome.”
| "Green syndrome" is a serious (hypothetical) chronic disease that presents with a period of mild illness, which, if left untreated, can progress to a more serious disease with a 5% risk of becoming a wheelchair user within 20 years. There is an effective treatment "Viridian" which can prevent progression of the syndrome. However, this is costly at £30,000 ($50,000 or €35,000) and has a high risk of side effects: 30% of patients suffer hair loss and 10% experience jaundice, although symptoms recover on cessation of treatment. |
| A 35 year old woman (Debbie) presents to you with new symptoms. Based on her clinical history, physical examination and symptoms, you really can't decide if she does or does not have "Green Syndrome". This means that your pre-test probability for disease is 50%. |
| A new test, the "anti-celadon test", which is cheap and based on a simple blood sample, has recently become available. Previously the only available test required a brain biopsy which had associated morbidity and very rarely mortality, but has 100% specificity and 95% sensitivity. You decide to order the anti-celadon test as you are unsure of the diagnosis. You find the key paper on the anti-celadon test to get further information on its accuracy. |
Characteristics of participants.
| Text-only | Nomogram | Probability modifying plot | Natural frequencies | ||
|---|---|---|---|---|---|
| N = 255 | N = 194 | N = 218 | N = 207 | ||
| Age group | 20–29 | 30 (11.8%) | 39 (20.1%) | 32 (14.7%) | 46 (22.2%) |
| 30–34 | 52 (20.4%) | 49 (25.3%) | 39 (17.9%) | 37 (17.9%) | |
| 35–39 | 49 (19.2%) | 36 (18.6%) | 46 (21.1%) | 42 (20.3%) | |
| 40–44 | 51 (20.0%) | 21 (10.8%) | 30 (13.8%) | 26 (12.6%) | |
| 45–49 | 27 (10.6%) | 21 (10.8%) | 21 (9.6%) | 13 (6.3%) | |
| 50–54 | 23 (9.0%) | 10 (5.2%) | 22 (10.1%) | 18 (8.7%) | |
| 55–59 | 16 (6.3%) | 11 (5.7%) | 10 (4.6%) | 12 (5.8%) | |
| 60+ | 7 (2.8%) | 7 (3.6%) | 18 (8.3%) | 13 (6.3%) | |
| Sex | Male | 153 (60.0%) | 112 (57.7%) | 122 (56.0%) | 124 (59.9%) |
| Professional status | GP | 30 (11.9%) | 23 (11.9%) | 29 (13.4%) | 11 (5.4%) |
| Consultant | 89 (35.2%) | 57 (29.5%) | 69 (31.8%) | 62 (30.2%) | |
| Trainee GP | 14 (5.5%) | 4 (2.1%) | 6 (2.8%) | 11 (5.4%) | |
| Trainee junior doctor | 91 (36.0%) | 88 (45.6%) | 85 (39.2%) | 88 (42.9%) | |
| Other | 29 (11.5%) | 21 (10.9%) | 28 (12.9%) | 33 (16.1%) | |
| Postgraduate training in evidence-based medicine of clinical epidemiology | Yes | 89 (35.3%) | 66 (34.9%) | 79 (36.6%) | 64 (31.5%) |
| No | 163 (64.7%) | 123 (65.1%) | 137 (63.4%) | 139 (68.5%) | |
| How confident are you in your ability to interpret data (e.g. sensitivity, specificity) from diagnostic research studies on the performance of diagnostic tests? | 1 (not at all) | 22 (8.7%) | 18 (9.5%) | 17 (7.8%) | 13 (6.4%) |
| 2 | 66 (26.2%) | 54 (28.4%) | 51 (23.5%) | 54 (26.6%) | |
| 3 | 98 (38.9%) | 76 (40.0%) | 94 (43.3%) | 97 (47.8%) | |
| 4 | 63 (25.0%) | 37 (19.5%) | 52 (24.0%) | 35 (17.2%) | |
| 5 (extremely) | 3 (1.2%) | 5 (2.6%) | 3 (1.4%) | 4 (2.0%) | |
| Mean (SD) number of correct answers to questions about diagnostic tests | 2.1 (1.3) | 2.3 (1.3) | 2.2 (1.2) | 2.2 (1.3) |
‡ See Table A in for more detailed breakdown.
Results by randomisation to method of presenting diagnostic test results.
| Clinical management | Post-test probability | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Treatment | Biopsy | No treatment | Don’t know or blank | Odds Ratio (95% CI) | Correct | Incorrect | Don’t know or blank | Odds Ratio (95% CI) | |
| Text-only (N = 255) | 142 (55.7%) | 79 (31.0%) | 31 (12.2%) | 3 (1.2%) | 1.00 (reference) | 30 (11.8%) | 218 (85.5%) | 7 (2.8%) | 1.00 (reference) |
| Nomogram (N = 194) | 112 (57.7%) | 56 (28.9%) | 24 (12.4%) | 2 (1.0%) | 1.09 (0.75, 1.58) | 50 (25.8%) | 137 (70.6%) | 7 (3.6%) | 2.60 (1.58, 4.29) |
| Probability modifying plot (N = 218) | 142 (65.1%) | 57 (26.2%) | 16 (7.3%) | 3 (1.4%) | 1.49 (1.02, 2.16) | 87 (39.9%) | 129 (59.2%) | 2 (0.9%) | 4.98 (3.12, 7.95) |
| Natural frequencies (N = 207) | 133 (64.3%) | 55 (26.6%) | 18 (8.7%) | 1 (0.5%) | 1.43 (0.98, 2.08) | 73 (35.3%) | 129 (62.3%) | 5 (2.4%) | 4.09 (2.54, 6.58) |